|
Market Closed -
NYSE
01:30:00 18/08/2026 am IST
|
5-day change | 1st Jan Change | ||
| 2.290 USD | +3.15% |
|
-7.66% | +27.22% |
| 12/08 | Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 | |
| 12/08 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Protalix BioTherapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 184.5 | - | - |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 27.46% | - | - |
| Enterprise Value (EV) | 37.89 | 69.41 | 129.9 | 138.4 | 144.8 | 184.5 | 184.5 | 184.5 |
| Change | - | 83.2% | 87.08% | 6.6% | 4.57% | 27.46% | 0% | 0% |
| P/E | -1.34x | -4.42x | 19.8x | 47x | -22.5x | 12.1x | 41.6x | 115x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | -0.8x | 0x | -0x | -0.6x | -1.8x |
| Capitalization / Revenue | 0.99x | 1.46x | 1.98x | 2.59x | 2.74x | 2.31x | 2.71x | 2.68x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 2.31x | 2.71x | 2.68x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | 0x | -0x | 10.1x | 54.6x | 163x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.62 | -0.31 | 0.09 | 0.04 | -0.08 | 0.19 | 0.055 | 0.02 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 38.35 | 47.64 | 65.49 | 53.4 | 52.74 | 79.8 | 68.19 | 68.82 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.46 | -13.01 | 10.46 | 3.917 | -5.5 | 18.35 | 3.378 | 1.131 |
| Net income 1 | -27.58 | -14.93 | 8.312 | 2.932 | -6.604 | 15.38 | 4.463 | 1.518 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 0.832 | 1.370 | 1.780 | 1.880 | 1.800 | 2.290 | 2.290 | 2.290 |
| Nbr of stocks (in thousands) | 45,557 | 50,666 | 72,952 | 73,634 | 80,421 | 80,572 | - | - |
| Announcement Date | 31/03/22 | 27/02/23 | 14/03/24 | 17/03/25 | 18/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 12.05x | - | - | - | 18Cr | |
| 33.85x | 12.21x | 24.91x | 0.58% | 1,05500Cr | |
| 29.18x | - | - | 2.05% | 63TCr | |
| 31.95x | 7.44x | 15.46x | 2.74% | 44TCr | |
| 19.84x | 4.71x | 11.68x | 2.81% | 35TCr | |
| 21.63x | 5.59x | 13.89x | 2.87% | 29TCr | |
| 20.07x | 4.15x | 11.78x | 2.12% | 24TCr | |
| 26.53x | 6.9x | 12.24x | 2.4% | 23TCr | |
| 13.3x | 4.74x | 9.93x | 3.86% | 20TCr | |
| -42.45x | 6.16x | 24.05x | 2.37% | 17TCr | |
| Average | 16.60x | 6.49x | 15.49x | 2.42% | 36.13TCr | |
| Weighted average by Cap. | 24.29x | 8.06x | 17.79x | 1.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PLX Stock
- Valuation Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
